RedHill Biopharma Ltd. Presents New Talicia Data Analyses at DDW 2022. Talicia is the leading FDA-approved brand for H. pylori treatment. The infection affects approximately 35% of the U.S. adult population, representing significant unmet need.
💼 Business Developments:
✅ Partnership/Collaboration
✅ Acquisition Activity
❌ Licensing Agreement: Not reported
✅ Regulatory Milestone
❌ Leadership Updates: Not reported
📞 Contact Information:
Media Contact: s: U.S. / UK: Amber Fennell, Consilium +44 (0) 7739 658 783 fennell@consilium-co
🌍 RedHill Biopharma (RDHL) - Form 6-K Filing
Filing Date: 2022-05-25
Accepted: 2022-05-25 09:17:04
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: